Swedish healthtech company Sigrid has released positive results of a study exploring the efficacy of its flagship metabolic health product, Glucose Stabiliser.
This follows the results of a consumer survey, which found that the patented dietary supplement reduced bloating in 92% of participants, while enhancing feelings of satiety in 93% of users.
Glucose Stabiliser is powered by SiPore mineral technology, which is a silica-based technology that traps enzymes responsible for the breakdown of fat and sugar — slowing digestion and reducing excess absorption.
In a previous interview with NBR, the company's Head of Product Development, Ghislaine Robert-Nicoud, told us that the ingredient primarily works by "promoting slower digestion and long-lasting fullness," contributing to the reduction of cravings and improved digestive comfort.
The study
The recent two week placebo-controlled clinical study assessed the benefits of Glucose Stabiliser in 20 healthy adults aged between 18 and 64.
In the two-phase trial, participants were required to wear a continuous glucose monitors, and each individual was given Glucose Stabiliser for 7 days followed by a placebo for the remainder of the study.
During the trial period, researchers found that participants maintained optimal glucose levels for significantly longer when taking Glucose Stabiliser.
Hypoglycaemic events were also reduced by an average of 85% compared with placebo, suggesting that daily intake of Glucose Stabiliser could improve metabolic stability significantly.
"The data we collated in this study definitively confirms our mode of action, with participants experiencing a notable improvement when switching from placebo to Glucose Stabiliser," noted Sana Alajmovic, CEO and co-founder of Sigrid.
"Volunteers remained in the optimal glucose range for almost 100% of the time when taking Glucose Stabiliser, and there was a notable reduction in hypoglycaemic events."
"Through continuous glucose monitoring, the impact is immediately visible — aligning with the results of our previous consumer survey and proving the efficacy of the product," she added.
Sigrid's US breakthrough
As the weight management potential of Glucose Stabiliser continues to be shown in clinical and consumer studies, Sigrid reports its success in the bustling US market.
The company entered its fifth month of consecutive US growth in May, with +41% net sales growth from April, and an 18% increase in new customer net sales.
Sigrid also claims to be operating on a 68% net margin, which is driven by higher recurring revenue from updated subscriptions.
“These results demonstrate that we’re not only delivering clinically validated benefits, but also engaging effectively in a high-demand market,” noted Alajmovic.
“Moving forward, we believe that Sigrid is well-positioned for rapid and profitable scaling," she concluded.